CELC Stock: Price, Earnings History and SEC Filings
Celcuity Inc. (CELC) last traded at $69.13, down 0.25% on the latest session and down 13.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.44 against an analyst estimate of $-1.08, a miss of 33.3%.
$69.13 -0.25%
1 month-13.07%
52-week high$151.02
52-week low$53.54
Volume700,081
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
CELC earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 13, 2026 | $-1.44 | $-1.08 | -33.33% |
| Mar 2026 | May 14, 2026 | $-0.97 | $-1.07 | +9.35% |
| Dec 2025 | Mar 25, 2026 | $-0.97 | $-1.06 | +8.49% |
| Sep 2025 | Nov 12, 2025 | $-0.92 | $-1.05 | +12.38% |
CELC beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for CELC
SEC filing data is not available right now. You can search for CELC on SEC EDGAR.
CELC news
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallOct 29, 2026 · finance.yahoo.com
- Will Breast And Prostate Cancer Data Change Celcuity (CELC) NarrativeOct 25, 2026 · finance.yahoo.com
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026Oct 24, 2026 · finance.yahoo.com
- Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026Oct 23, 2026 · finance.yahoo.com
- Cantor sees ‘credible path to multi-billion-dollar peak sales’ for CelcuityOct 22, 2026 · finance.yahoo.com
About Celcuity Inc.
Celcuity Inc. (CELC) is a US-listed public company on Nasdaq.